Kornimate/medical-research-clean huggingface dataset:
the effect of continuous renal replacement therapy on the efficiency of extracorporeal co2 removal

Conditions: Respiratory Failure With Hypercapnia

Summary: in the design of extracorporeal carbon dioxide removal (ecco2r) combined with continuous renal replacement therapy (crrt) equipment, in model of continuous veno-venous hemofiltration (cvvh) , the hco3- concentration in the pre membrane lung blood is diluted by the replacement solution, and a decrease in hco3- leads to a decrease in pco2. on the other hand, in continuous veno-venous hemodialysis (cvvhd), hco3- in post membrane blood will exchange interaction. the exchange results of hco3- determine the impact of cvvhd on the co2 removal efficiency of the ecco2r combined crrt system. this study aims to investigate the effects of cvvh and cvvhd on in vitro co2 clearance efficiency.

in the design of extracorporeal carbon dioxide removal (ecco2r) combined with continuous renal replacement therapy (crrt) equipment, the pre dilution replacement solution for continuous veno-venous hemofiltration (cvvh) enters the extracorporeal bloodstream upstream of the membrane lung, so the hco3- concentration in the pre membrane lung blood is diluted by the replacement solution. hco3- and dissolved co2 are in a dynamic and rapid equilibrium state, and a decrease in hco3- leads to a decrease in pco2. on the other hand, in continuous veno-venous hemodialysis (cvvhd), the blood after the membrane needs to undergo material exchange with the dialysate through a filter. the dialysate is usually hco3- with normal plasma concentration, so hco3- in post membrane blood will exchange interaction. the exchange results of hco3- determine the impact of cvvhd on the co2 removal efficiency of the ecco2r combined crrt system. this study aims to investigate the effects of cvvh and cvvhd on in vitro co2 clearance efficiency.

Eligibility criteria:
inclusion criteria: * using extracorporeal carbon dioxide removal combined with continuous renal replacement therapy * 18 years ≤ age ≤ 85 years; exclusion criteria: * severe hemodynamic instability (increased dosage of vasoactive drugs or map ≤ 65mmhg within two hours); * severe electrolyte deficiency (including severe hyponatremia (blood sodium\<130mmol/l) and hypokalemia (blood potassium\<3.0mmol/l)); * participate in other intervention studies within 30 days; * do not consent this research
comparative efficacy of different mebendazole polymorphs in the treatment of soil-transmitted helminth infections

Conditions: Necator Americanus Infection

Summary: mebendazole tablets which are produced by most pharmaceutical manufacturers, including the state pharmaceutical manufacturing corporation (spmc) of sri lanka, contain a mixture of polymorphs a and c. however, there is some evidence to show that mebendazole polymorph c is the only form effective against the soil-transmitted helminths. this protocol describes a stratified, randomized, placebo-controlled trial that examined the efficacy of different mebendazole polymorphs produced by the spmc in the treatment of hookworm infections.

mebendazole has three polymorphic forms, identified as a, b and c. all of them are in accord with the us pharmacopeia specifications (usp xxi) but they have distinct physiochemical characteristics (himmelreich et al, 1977) and different therapeutic activities in experimentally infected mice with trichinella spiralis infections (rodriguez-caabeiro et al, 1987). the original mebendazole tablets which were used to treat human infections had more than 90% of polymorph c (van den bossche et al, 1982), but most pharmacopeias currently do not specify the proportion of polymorph c that a tablet of mebendazole should contain, and the assay specified for measurement of the active ingredient measures all polymorphs together. there is some evidence to show that unlike polymorph c, polymorph a is ineffective in the treatment of hookworm and whipworm infections (charoenlarp et al, 1993). the state pharmaceutical manufacturing corporation of sri lanka produces both 500 mg and 100 mg tablets of mebendazole according to specifications laid down in the us pharmacopeia. these tablets contain a mixture of polymorphs a and c. it is possible that increasing the content of mebendazole polymorph c in single dose tablets may improve cure rates and egg reduction rates, especially against hookworm and whipworm infections, where much variation in efficacy has been observed.

Eligibility criteria:
inclusion criteria: * necator americanus infection, as determined by examination of a single faecal smear, alone or with ascaris lumbricoides or trichuris trichiura exclusion criteria: * children below the age of 2 years * pregnant women * individuals with diarrhea on day of treatment

Keywords: hookworm necator americanus mebendazole
verbal encouragement in swimming

Conditions: Healthy

Summary: verbal encouragement (ve) is used to enhance the performance in several sports, even though no studies have been conducted in swimmers and no effects have been reported in elite athletes by some authors. besides influencing motor performance, ve is also known to enhance the physical load, thus increasing the probability of developing fatigue. the aim of this research was to study ve in swimmers by evaluating both chronometric performance and muscle fatigue (using semg).


Eligibility criteria:
inclusion criteria: * at least 1 year of experience in training aimed at regional and international competitions * a score ≥ 200 points on the personal best in the 200m freestyle, in accordance with the international point score (ips) (http://www. swimnews.com/ipspoints) * being healthy exclusion criteria: * having a disease

Keywords: verbal encouragement performance muscle fatigue swimming semg
fapi pet/ct in various fap-related disease patients

Conditions: FAP-related Disease; Tumor; Positron Emission Tomography; Metastasis

Summary: to evaluate the potential usefulness of 68ga/18f-fapi positron emission tomography/computed tomography (pet/ct) for the diagnosis of primary and metastatic lesions in various fap-related disease patients.

subjects with various fap-related disease patients underwent 68ga/18f-fapi pet/ct either for an initial assessment or for recurrence detection. lesions uptake was quantified by the maximum standard uptake value (suvmax). the sensitivity, specificity, positive predictive value (ppv), negative predictive value (npv) and accuracy of 68ga/18f-fapi pet/ct were calculated.

Eligibility criteria:
inclusion criteria: * (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include mri, ct, tumor markers and pathology report); (iii) patients who had scheduled fapi pet/ct scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the clinical research ethics committee. exclusion criteria: * (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

Keywords: pet/ct fap fapi
genome scan for obesity in a multi-ethnic sample

Conditions: Cardiovascular Diseases; Heart Diseases; Obesity

Summary: to scan the genome for obesity in a multi-ethnic sample.

background: despite intensive efforts the genetic basis of obesity has been difficult to establish. linkage analysis using a genome-wide scan can potentially identify genomic regions not previously thought to be associated with susceptibility to obesity and provides a comprehensive test of the consistency of previous studies. the study used the considerable resources generated by the four cooperating networks in the nhlbi-supported "family blood pressure program" (fbpp) to conduct a genome-wide scan data for obesity. design narrative: in the family blood pressure program, microsatellite markers were typed at a density of -10cm by the mammalian genotyping service (mgs) in marshfield, wi. the complete data set was to include 9,940 individuals representing 4 ethnic groups (white, black, hispanic and asian). obesity was characterized as a weight/height ratio (body mass index) and waist/hip ratio. this data set was larger than any prior genome scan for obesity, and the inclusion of multiple ethnic groups made it possible to examine genetic heterogeneity. the specific aims of the study were to conduct linkage and association analyses to localize regions influencing obesity. investigators worked closely with the fbpp coordinating center (washington university, st. louis) and investigators from each of the four fbpp networks. evidence was sought for consistency between results obtained from analyses of the genome scan performed by each of the individuals, and results summarized from the literature, with those found in meta-analysis. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
microorganosphere (mos) drug screen pilot trial in colorectal cancer

Conditions: Colorectal Neoplasms

Summary: the purpose of the study is to determine the feasibility of generating sufficient microorganospheres (mos) from a biopsy of a subject's adenocarcinoma of the colon and/or rectum that is metastatic to the liver and completing a drug screen against patient-derived mos using standard of care drugs used in the treatment of colorectal cancer (oxaliplatin, irinotecan, 5-fu/capecitabine (xeloda), bevacizumab, panitumumab or cetuximab, trifluridine/tipiracil (lonsurf), regorafenib and pembrolizumab or nivolumab) in ≤ 14 days.


Eligibility criteria:
key inclusion criteria: * subject signed a valid, institutional review board (irb)/ethics committee (ec)-approved informed consent form. * male or female age 18 or older when written informed consent is obtained. * study candidate is willing and able to comply with all protocol-required procedures and assessments. * study candidate either 1. is scheduled for or plans to be scheduled for a biopsy of the liver or 2. has a previous histologically or cytologically confirmed diagnosis of adenocarcinoma of the colon and/or rectum that is metastatic to the liver. key exclusion criteria: * if already scheduled for a biopsy of the liver: liver biopsy was ordered to help diagnose, determine the severity of, or treat a disease that is unrelated to colorectal cancer (e.g., nonalcoholic fatty liver disease, chronic hepatitis b or c, autoimmune hepatitis, alcoholic liver disease, primary biliary cirrhosis, primary sclerosing cholangitis, hemochromatosis, wilson's disease, etc.). * study candidate is participating (or intends to participate) in another clinical study and either: 1. is currently receiving investigational systemic therapy for adenocarcinoma of the colon and/or rectum that is metastatic to the liver as part of that study or 2. that study only allows investigational systemic therapy for adenocarcinoma of the colon and/or rectum that is metastatic to the liver (simultaneous participation in a clinical trial standard of care control arm is allowed, provided the subject is either already randomized or may be randomized to the control arm). * confirmed histological or cytological diagnosis of neuroendocrine colorectal cancer.

Keywords: liver metastasis colorectal cancer colon cancer crc liver metastasis patient-derived model
stat3 in t cells: at the crossroads of inflammation and cancer

Conditions: Cutaneous T Cell Lymphoma

Summary: protocol summary constitutive stat3 activity is implicated in many malignancies including cutaneous t cell lymphoma. it is also essential for th17 differentiation, a subset of cd4 effector t cell, implicated in chronic inflammatory conditions and possibly ctcl. hdac inhibitors have shown activity in ctcl but their exact mechanism of action is not known. it is known that hdac inhibitors regulate stat3 transcriptional activity and hence can potentially be active in ctcl through modulation of the stat3 pathway. the hypothesis is that th17 cytokines contribute to the initiation of cancer by creating a pro-inflammatory microenvironment that predisposes cells to neoplastic transformation. to probe this, the investigators will compare the differences in cytokine production and gene expression in the skin resident t cells from patients with benign dermatoses and ctcl as well as in the blood/circulating lymphocytes of healthy donors and sezary syndrome (ss). the investigators will also investigate whether hdac inhibitors have a direct impact on the number of th17 cells, the cytokine production by these cells and phosphorylated stat3 protein in ctcl with subsequent treatment cycles. the objectives of this study are 1. observe the epigenetic, transcriptional and phenotypic changes that take place in t cell during malignant transformation 2. understand the mechanism of action of hdac inhibitors in ctcl. methods: skin biopsy specimens from cutaneous t cell lymphoma (ctcl) patients and benign skin conditions namely eczema, dermatitis and psoriasis will be obtained through a standard punch biopsy procedure from the skin lesion. additionally, 15 ml of peripheral blood from ctcl patients who have sezary syndrome (ss) and from patients with benign skin condition will be collected. ctcl patients, who are starting treatment with hdac inhibitors namely vorinostat and romidepsin, will have a total of 3 skin biopsies and/or blood draws. the first procedure would be before starting treatment with either of these hdac inhibitors. two more skin biopsies and/or blood draws will be performed after first and second cycle of treatment. levels of th17 cytokines, il-17, il -22 and pstat3 protein will be determined by ihc staining in the skin and cytokine levels in the blood will be assayed by sandwich elisa method.the investigators will also assay the mrna levels of the transcription factors of the different t effector cells by qpcr.


Eligibility criteria:
inclusion criteria: * adult patients with ctcl that are starting new form of treatment and adult patients with benign dermatoses. exclusion criteria: * patients with lymphomas other than ctcl or leukemia
an observational study to understand challenges associated with progression of insulin therapy in type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this study is to identify specific patient, physician, and health system related factors associated with the progression to a more intensive regimen from initial insulin therapy for patients with type 2 diabetes.


Eligibility criteria:
inclusion criteria: * have been diagnosed with type 2 diabetes * have presented within the normal course of care * have been on their initial insulin therapy for ≥3 months (with or without any combination of approved non-insulin anti-diabetic medications) * are not simultaneously participating in a study that includes an investigational drug or procedure at entry into the study * have been fully informed and have given written consent for the use of their data * have a sufficient understanding of the primary language of the country such that they will be able to complete the questionnaires * have not initiated basal bolus therapy (three mealtime insulin injections) exclusion criteria: * none

Keywords: diabetes insulin progression patient reported measures adherence heterogeneity hypoglycemia
the effect of a multi-intervention program and protein food sources on preventing and mitigating sarcopenia

Conditions: Sarcopenia; Dietary Exposure; Nutrition, Healthy; Bone Health; Muscle Function; Muscle Performance

Summary: sarcopenia is characterized by loss of skeletal muscle mass and strength with advancing age. it is linked to an increased risk of falls, disability, length of hospitalization, poor quality of life, and burden of health care. nutrition and physical activity are the major modifiable factors to prevent and mitigate sarcopenia. however, most studies focused on the explore the effects of physical activity or single nutrient supplementation. whether a multi-intervention program combining protein-rich food intake, nutrition education, and exercise can more effectively reduce the risk of sarcopenia still needs to be explored at the community level. this study aimed to investigate the effects of a multi-intervention program (protein-rich food supplement, nutrition education, and exercise) on reducing the risk of sarcopenia. the primary outcome is to evaluate the effect of a multi-intervention program and exercise intervention only. the second outcome is to assess the impact of animal and plant source protein on muscle mass and physical performance. investigators will recruit the study participants over the age of 60 from the free-living community. all participants were randomized into five groups: animal protein, plant protein, exercise and nutrition education, exercise alone, and control. for 8 weeks, except for control group, all four groups receive resistance training 3 times/week. however, the animal and plant protein groups provide milk 240 ml and soy milk 230 ml (7-8 g protein/serving) after exercise, respectively, and receive personal nutritional counseling and education to adhere to dietary recommendations. dual-energy x-ray using to evaluate the body composition and measure the grip strength, five-time chair stand test, and gait speed to assess physical performance pre- and post-intervention. the results of this study can be used to prevent muscle mass loss and frailty for older adults in the community.


Eligibility criteria:
inclusion criteria: * over the age of 60 from the free-living community exclusion criteria: * kidney patients, diabetics, cancer patients, moderate/severe cognitively impaired, disability, those who take any commercial protein nutritional supplements, those who are underweight, vegans, food allergy to dairy products and soy products

Keywords: sarcopenia protein exercise nutritional education bone health
mifepristone (ru-486) in androgen independent prostate cancer

Conditions: Prostate Cancer; Adenocarcinoma of Prostate

Summary: the purpose of this study is to determine the effects (good and bad) that mifepristone has on patients with androgen independent prostate cancer.

patients will receive mifepristone, 200mg orally once a day. one treatment cycle is 28 days long. patients will remain on treatment unless their cancer gets worse or they develop intolerable side effects. at the end of each cycle a physical examination, routine blood tests, and hormone levels will be performed. after every 3 cycles, one or more of the following will be performed: bone scan, chest x-ray, ct scan or mri.

Eligibility criteria:
inclusion criteria: * histologic documentation of adenocarcinoma of the prostate * bone metastasis(es) by bone scan or cat scan * clinical, biochemical, or radiographic progression after primary androgen ablation with either orchiectomy or gonadotropin releasing hormone analog therapy. * one prior chemotherapy treatment is allowed. * \> 3 weeks since major surgery * \> 4 weeks since radiotherapy * \> 8 weeks since prior strontium-89 or samarium 153 * ecog performance status 0 or 1 * absolute neutrophil count (anc) \> 1,500/ul * platelets \> 100,000/ul * bilirubin \< 1.5 x upper limit of normal (uln) * ast or alt \< 3 x uln * creatinine \< 1.5 x uln * electrolytes within 10% of normal range * serum testosterone \< 50ng/dl * prostate-specific antigen (psa) \> 5.0ng/ml exclusion criteria: * concomitant therapy with corticosteroids * chemotherapy within 28 days * currently active second malignancy other than non-melanoma skin cancer * baseline adrenal insufficiency requiring long-term steroids

Keywords: androgen independent prostate cancer prostate cancer mifepristone ru-486
brief anxiety sensitivity treatment for obsessive compulsive symptoms

Conditions: Obsessive-Compulsive Disorder and Symptoms

Summary: obsessive-compulsive disorder (ocd), characterized by recurrent obsessions and/or compulsions, is a disabling psychiatric condition affecting approximately 2-3% of the population. whereas several first-line treatments have been established (e.g., pharmacological and psychological), a substantial proportion of patients (40-60%) fail to experience symptom remission, underscoring the need for research in this area. one approach to increasing treatment efficacy is to target underlying risk factors or dysfunctions that may in turn improve outcomes. one such risk factor is anxiety sensitivity (as) cognitive concerns. as cognitive concerns reflects fears of mental incapacitation (e.g., "it scares me when i am unable to keep my mind on a task"). there is recent evidence that as cognitive concerns is uniquely associated with various obsessive-compulsive (oc) symptom domains. however, questions remain as to whether reductions in as cognitive concerns will lead to subsequent reductions in oc symptoms. the purpose of the proposed study is to investigate the efficacy of a brief as cognitive concerns intervention on reductions in oc symptoms.


Eligibility criteria:
inclusion criteria: * participants must be 18 years of age or older * elevated levels of obsessive-compulsive symptoms as indicated by scoring one standard deviation above the non-clinical mean on any dimensional obsessive-compulsive scale dimension * elevated anxiety sensitivity cognitive concerns as indicated by scoring one standard deviation above the non-clinical mean exclusion criteria: * evidence of a significant medical illness that would prevent the completion of interoceptive exposure (ie) exercises * non-english speakers * individuals currently receiving cognitive-behavioral therapy for anxiety and/or mood disorders or who are not stable on psychotropic medications (i.e., new medication or changes in dosage within the last three months)

Keywords: obsessive-compulsive disorder ocd anxiety sensitivity cognitive concerns
localized therapeutics for the treatment of gastrointestinal disorders ii

Conditions: Colitis, Ulcerative

Summary: the purpose of this study is to investigate a novel thermosensitive topical gel formulation for the treatment of inflammatory bowel disease (ibd), specifically ulcerative colitis.


Eligibility criteria:
inclusion criteria: * voluntarily sign written informed consent. * male or non-pregnant and non-lactating females at least 8 years of age. * confirmed diagnosis of active, mild to moderate ulcerative proctitis or proctosigmoiditis extending no further than 40cm from the anal verge. typically, baseline mayo disease activity index (mmdai) score between 5 and 10 (indicating mild to moderate disease). exclusion criteria: * known infection with clostridium difficile (c. difficile) and/or other enteric pathogens * 5-aminosalicylic acid (5-asa) intolerance * current or recent (3 weeks) oral or rectal steroids * history of thiopurine or anti-tumor necrosis factor (anti-tnf) alpha treatment for colitis * abnormal creatinine * previous small bowel or colonic resection, * anal sphincter incompetence, * current smokers. * history or current diagnosis of crohn's disease or indeterminate colitis. * history of diverticulitis, collagenous colitis, celiac disease, recurrent pancreatic or known gallbladder disease. * unstable significant cardiovascular, endocrine, neurologic or pulmonary disease. * hemoglobin levels \< 7.5 g/dl. * history of sclerosing cholangitis, cirrhosis, or hepatic impairment * pregnant or at risk of pregnancy. * some medications to treat uc are prohibited during participation in the study, including laxatives and anti-diarrhea medications; oral 5-asa agents and daily fiber supplements are allowed.

Keywords: enema ulcerative colitis